M4MM

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Bioxyne Double-Strikes in LATAM and Europe

SYDNEY – Bioxyne Limited, an international health and life sciences company focused on the manufacturing and distribution of novel medicines, including medical Cannabis, psilocybin, and MDMA, has signed two new commercial agreements – one stretching ...

Rubicon Organics Reports Q1 2026 Financial Results

VANCOUVER – Rubicon Organics Inc. delivered its first-quarter report, revealing results that show both progress and short-term pressures common in an industry shifting toward larger-scale operations – all while balancing strong market share gains with ...

Otsuka Completes $1.23B Buyout of Transcend Therapeutics

PRINCETON – Otsuka America, the U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., announced that it has completed its acquisition of Transcend Therapeutics, a New York biotechnology company developing rapid-acting treatments for neuropsychiatric disease. First disclosed ...

Texas Broadens Medical Cannabis Access Amid THC Policy Shift

LOS ANGELES- Texas has enacted House Bill 46, expanding its Compassionate Use Program for medical cannabis. The law, effective September 1, adds qualifying conditions such as chronic pain, Crohn’s disease and traumatic brain injury. It raises the per‑dose ...

Cronos Expands Medical Cannabis Presence in Switzerland

LOS ANGELES- Cronos Group Inc. has entered the Swiss medical cannabis market through a partnership with Dascoli Pharma AG, a Zurich-based pharmaceutical distributor. The deal enables Dascoli to supply five varieties of the company's PEACE NATURALS branded ...

Subscribe To Our Newsletter